SBC Medical Group Updates Capital Strategy

By Chris Stiles • Wednesday, December 31 10:32 • Permanent Link

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) has recently announced an updated capital strategy for future growth. The company's Form S-3 registration statement was declared effective by the U.S. Securities and Exchange Commission (SEC) on December 30, 2025, enabling it to offer and sell up to $50 million of common stock or preferred stock on a primary basis. This provides greater flexibility for future capital raising to facilitate growth, including domestic and international mergers and acquisitions (M&A).

The Form S-3 also covers securities related to the company’s business combination transaction that closed on September 17, 2024, including securities being sold by selling securityholders, which were previously registered on the company’s registration statement on Form S-1.

Additionally, the company's board of directors has authorized a $20.0 million share repurchase program, which allows for the repurchase of shares of its common stock from time to time through open market transactions, privately negotiated transactions, or other means. The repurchase program terminates on December 31, 2026, and may be modified, suspended, or discontinued at any time in the company’s discretion.

SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, aga (hair restoration), and ophthalmology. The company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia.

In September 2024, the company was listed on NASDAQ, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. The company continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care. Today the company's shares have moved -0.91% to a price of $4.34. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.